Alex Pizzini1, Francesco Burkert1, Igor Theurl1, Günter Weiss1, Rosa Bellmann-Weiler2. 1. Department of Internal Medicine II, Infectious Diseases, Pneumology, Rheumatology, Medical University of Innsbruck, Innsbruck, Austria. 2. Department of Internal Medicine II, Infectious Diseases, Pneumology, Rheumatology, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: rosa.bellmann-weiler@i-med.ac.at.
Abstract
BACKGROUND: Seasonal influenza is an important cause of morbidity and mortality worldwide and cardiac injuries are dangerous complications of influenza infection. Cardiac troponins are established biomarkers of myocardial damage. OBJECTIVE: The aim of the study was to assess high sensitive Troponin-T (hsTnT) serum levels as a surrogate parameter of cardiac involvement in influenza patients. METHODS: Cross-sectional analysis of 264 patients with laboratory-confirmed influenza virus infection. Routine laboratory parameters, hsTNT, and the history of cardiovascular disease were included in the analysis. Assessed prognostic endpoints were inpatient therapy requirement, death < 30 days after hospitalization and acute cardiac events (ACE) defined as myocardial ischemia, heart failure or new arrhythmia requiring therapy. RESULTS: Eighty-four patients (31.8%) had increased hsTnT at the initial presentation and twenty patients (7.6%) experienced ACE. Patients with ACE had higher hsTnT (p < 0.01) and CRP (p = 0.04) serum levels compared to patients who did not experience ACE. A binary logistic regression model to predict ACE revealed hsTnT (p < 0.01) and CRP (p = 0.01) to significantly influence the odds for ACE. A hsTnT cut-off of 46,4 ng/l was identified as having the best discriminative potential to identify patients with ACE (sensitivity = 0.7, specificity = 0.8). CONCLUSION: To date, this is the largest available analysis of the specific cardiac marker hsTnT in patients with influenza. A slight elevation of hsTnT is a common feature of patients with influenza, however increased hsTnT also highlights a higher risk for cardiac complications and fatal outcome.
BACKGROUND: Seasonal influenza is an important cause of morbidity and mortality worldwide and cardiac injuries are dangerous complications of influenza infection. Cardiac troponins are established biomarkers of myocardial damage. OBJECTIVE: The aim of the study was to assess high sensitive Troponin-T (hsTnT) serum levels as a surrogate parameter of cardiac involvement in influenzapatients. METHODS: Cross-sectional analysis of 264 patients with laboratory-confirmed influenza virus infection. Routine laboratory parameters, hsTNT, and the history of cardiovascular disease were included in the analysis. Assessed prognostic endpoints were inpatient therapy requirement, death < 30 days after hospitalization and acute cardiac events (ACE) defined as myocardial ischemia, heart failure or new arrhythmia requiring therapy. RESULTS: Eighty-four patients (31.8%) had increased hsTnT at the initial presentation and twenty patients (7.6%) experienced ACE. Patients with ACE had higher hsTnT (p < 0.01) and CRP (p = 0.04) serum levels compared to patients who did not experience ACE. A binary logistic regression model to predict ACE revealed hsTnT (p < 0.01) and CRP (p = 0.01) to significantly influence the odds for ACE. A hsTnT cut-off of 46,4 ng/l was identified as having the best discriminative potential to identify patients with ACE (sensitivity = 0.7, specificity = 0.8). CONCLUSION: To date, this is the largest available analysis of the specific cardiac marker hsTnT in patients with influenza. A slight elevation of hsTnT is a common feature of patients with influenza, however increased hsTnT also highlights a higher risk for cardiac complications and fatal outcome.
Authors: Luigi Biasco; Catherine Klersy; Giulia S Beretta; Marco Valgimigli; Amabile Valotta; Luca Gabutti; Roberto Della Bruna; Alberto Pagnamenta; Gregorio Tersalvi; Lorenzo Ruinelli; Andrea Artero; Gaetano Senatore; Peter Jüni; Giovanni B Pedrazzini Journal: Eur Heart J Open Date: 2021-08-30
Authors: Manuel Antonio Tazón-Varela; Jon Ortiz de Salido-Menchaca; Pedro Muñoz-Cacho; Enara Iriondo-Bernabeu; María Josefa Martos-Almagro; Emma Lavín-López; Ander Vega-Zubiaur; Edgar José Escalona-Canal; Iratxe Alcalde-Díez; Carmen Gómez-Vildosola; Ainhoa Belzunegui-Gárate; Fabiola Espinoza-Cuba; José Antonio López-Cejuela; Alba García-García; Alejandro Torrejón-Cereceda; Elena Sabina Nisa-Martínez; Diana Moreira Nieto; Cintia Hellín-Mercadal; Ander García-Caballero; Héctor Alonso-Valle Journal: J Pers Med Date: 2022-03-23
Authors: Muhammad Shahzeb Khan; Izza Shahid; Stefan D Anker; Scott D Solomon; Orly Vardeny; Erin D Michos; Gregg C Fonarow; Javed Butler Journal: BMC Med Date: 2020-12-18 Impact factor: 8.775
Authors: Peter Jirak; Vincent van Almsick; Dimitrios Dimitroulis; Moritz Mirna; Clemens Seelmaier; Zornitsa Shomanova; Bernhard Wernly; Dilvin Semo; Daniel Dankl; Magdalena Mahringer; Michael Lichtenauer; Uta C Hoppe; Holger Reinecke; Rudin Pistulli; Robert Larbig; Lukas J Motloch Journal: Front Med (Lausanne) Date: 2022-02-02
Authors: Lea Pitscheider; Mario Karolyi; Francesco R Burkert; Raimund Helbok; Julia V Wanschitz; Corinne Horlings; Erich Pawelka; Sara Omid; Marianna Traugott; Tamara Seitz; Alexander Zoufaly; Elisabeth Lindeck-Pozza; Ewald Wöll; Ronny Beer; Stefanie Seiwald; Rosa Bellmann-Weiler; Harald Hegen; Wolfgang N Löscher Journal: Eur J Neurol Date: 2020-10-25 Impact factor: 6.288